| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558, 2019 | 1015 | 2019 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 1009 | 2016 |
| Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ... Nature communications 5 (1), 5241, 2014 | 917 | 2014 |
| Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ... Cancer discovery 9 (5), 646-661, 2019 | 631 | 2019 |
| Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression DL Gibbons, W Lin, CJ Creighton, ZH Rizvi, PA Gregory, GJ Goodall, ... Genes & development 23 (18), 2140-2151, 2009 | 560 | 2009 |
| Treatment of non–small-cell lung cancer with erlotinib or gefitinib VD Cataldo, DL Gibbons, R Pérez-Soler, A Quintás-Cardama New England Journal of Medicine 364 (10), 947-955, 2011 | 541 | 2011 |
| Conformational change and protein–protein interactions of the fusion protein of Semliki Forest virus DL Gibbons, MC Vaney, A Roussel, A Vigouroux, B Reilly, J Lepault, ... Nature 427 (6972), 320-325, 2004 | 453 | 2004 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 436 | 2021 |
| A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ... Clinical Cancer Research 22 (3), 609-620, 2016 | 427 | 2016 |
| Epithelial–mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung … Y Lou, L Diao, ERP Cuentas, WL Denning, L Chen, YH Fan, LA Byers, ... Clinical Cancer Research 22 (14), 3630-3642, 2016 | 394 | 2016 |
| CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ... Cancer discovery 8 (9), 1156-1175, 2018 | 367 | 2018 |
| Smoking, p53 mutation, and lung cancer DL Gibbons, LA Byers, JM Kurie Molecular cancer research 12 (1), 3-13, 2014 | 305 | 2014 |
| Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ... Scientific reports 7 (1), 13380, 2017 | 256 | 2017 |
| Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion DH Peng, BL Rodriguez, L Diao, L Chen, J Wang, LA Byers, Y Wei, ... Nature communications 11 (1), 4520, 2020 | 238 | 2020 |
| miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1 JD Roybal, Y Zang, YH Ahn, Y Yang, DL Gibbons, BN Baird, C Alvarez, ... Molecular cancer research 9 (1), 25-35, 2011 | 231 | 2011 |
| The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200–dependent pathway in mice Y Yang, YH Ahn, DL Gibbons, Y Zang, W Lin, N Thilaganathan, ... The Journal of clinical investigation 121 (4), 1373-1385, 2011 | 228 | 2011 |
| The fibrotic tumor stroma M Yamauchi, TH Barker, DL Gibbons, JM Kurie The Journal of clinical investigation 128 (1), 16-25, 2018 | 227 | 2018 |
| Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. T Cascone, WN William, A Weissferdt, HY Lin, CH Leung, BW Carter, ... Journal of Clinical Oncology 37 (15_suppl), 8504-8504, 2019 | 202 | 2019 |
| A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model BJ Gill, DL Gibbons, LC Roudsari, JE Saik, ZH Rizvi, JD Roybal, JM Kurie, ... Cancer research 72 (22), 6013-6023, 2012 | 197 | 2012 |
| Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ... Annals of Oncology 28 (1), 75-82, 2017 | 194 | 2017 |
John HeymachChair, Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer CenterVerified email at mdanderson.org
